A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer

Annals of Oncology

Volumn 9, Issue 10, 1998, Pages 1085-1090

  Vokes, E E ^a,b   Ansari, R H ^a   Masters, G A ^a   Hoffman, P C ^a,b   Klepsch, A ^a   Ratain, M J ^a,b   Sciortino, D F ^a   Lad, T E ^a   Krauss, S ^a   Fishkin, P A S ^a   Golomb, H M ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

Author keywords

9 AC; Non small cell lung cancer

Indexed keywords

9 AMINOCAMPTOTHECIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TUMOR GROWTH;

AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 7844228404     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008432729754     Document Type: Article

References (31)

1. Ginsberg R, Vokes EE, Raben A. Non-small-cell lung cancer. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer - Principles and Practice of Oncology, 5th Edition. Philadelphia, PA: J.B. Lippincott Co. 1997; 858-910.
2. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
3. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small-cell lung cancer (NSCLC): Report of a southwest oncology group study (SWOG-9308). Proc Am Soc Clin Oncol 1996; 374 (Abstr 1110).
4. Bonomi P, Kim K, Chang A et al. Phase III trial comparing etoposide cisplatin versus Taxol with cisplatin G-CSF versus Taxol cisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 1996; 15: 382 (Abstr 1145).
5. Sandler A, Nemunaitis J, Dehnam C et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998; 17: 454 (Abstr 1747).
6. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 1995; 13 (10): 2643-55.
7. Takimoto CH, Arbuck SG: The Camptothecins. In Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA: Lippincott-Raven 1996; 463-84.
8. Rothenberg ML: Topoisomerase I inhibitors: Review and update. Ann Oncol 1997; 8: 837-55.
9. Muggia FM, Dimery I, Arbuck SG: Camptothecin and its analogs. An overview of their potential in cancer therapeutics. Ann NY Acad Sci 1996; 803: 213-23.
10. Rothenberg ML, Kuhn JG, Burris HA III et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-204.
11. De Forni M, Bugat R, Chabot GG et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan. administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-54.
12. Fukuoka M, Nitani H, Suzuki A et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10 (1): 16-20.
13. Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12 (1): 90-6.
14. Rowinsky EK, Grochow LB, Sartorius E et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996; 14: 1224-35.
15. Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14 (2): 503 13.
16. Lynch TJ, Kalish L, Strauss G et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12 (2): 347 52.
17. Pantazis P, Hinz HR, Mendoza JT et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 1992; 52: 3980-7.
18. Giovanella BC, Stehlin JS, Wall ME et al. DNA topoisomerase-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
19. Mattern MR, Hofmann GA, Polsky RM et al. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 1993; 5 (12): 467-74.
20. Pantazis P, Kozielski AJ, Vardeman DM et al. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 1993; 5 (8): 273-81.
21. Dahut W, Harold N, Takimoto C et al. A phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 1996; 14: 1236-44.
22. Rubin E, Wood V, Bharti A et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995; 1: 269-76.
23. Pazdur R, Diaz-Canton E, Ballard WP et al. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 1997; 15 (8): 2905-9
24. Saltz LB, Kemeny NE, Tong W et al. 9-aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 1997; 80 (9): 1727-32.
25. Kraut EH, Balcerzak SP, O'Rourke M et al. Phase II trial of 9-aminocamptothecin in patients with refractory breast cancer. Proc Am Soc Clin Oncol 1997; 16: 177 (Abstr 620).
26. Takimoto CH, Dahut W, Marino MT et al. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1994; 15 (Suppl 4): 1492 1501.
27. Vokes EE, Bitran JD. Non-small-cell lung cancer: Towards the next plateau. Chest 1994; 106: 659-61.
28. Non-Small-Cell Lung Cancer Collaborators Group: Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patient from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
29. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 1994; 12 (3): 553-9.
30. Hochster H, Potmesil M, Liebes J et al. A phase I study of 9-aminocamptothecin (9-AC) by prolonged infusion to 21 days. Ann Oncol 1996; 7 (Suppl 1): 130 (Abstr).
31. Takimoto CH, Dahut W, Harold N et al. A phase I trial of a prolonged infusion of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 1996; 15: 488 (Abstr 1554).